Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Clinical Trials for Molecular Targeted Agents / Immunotherapy / Biologics

113 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Molecular Targeted Agents / Immunotherapy / Biologics

Melanoma

VICCMEL12117

02/18/2013

A Multi-Site Retrospective Observational Study of US Patients with Unresectable or Metastatic Melanoma Receiving Ipilimumab (YERVOY?) as First-Line Therapy

Molecular Targeted Agents / Immunotherapy / Biologics

Neuroblastoma (Pediatrics)
Pediatric Solid Tumors

VICCPED12112

01/04/2013

NMTRC003: A Phase II Preventative Trial of DFMO (eflornithine HCI) as a Single Agent in Patients with High Risk Neuroblastoma in Remission

Molecular Targeted Agents / Immunotherapy / Biologics

Leukemia

VICCBMT15101

01/22/2016

A Randomized, Parallel-Cohort Phase 1 Study of INCB039110 in Combination With Corticosteroids for the Treatment of Grades II to IV Acute Graft-Versus-Host Disease

Molecular Targeted Agents / Immunotherapy / Biologics

Leukemia
Lymphoma

VICCBMT1501

04/22/2015

A Multicenter OpenLabel Phase 1b/2 Study of Ibrutinib in Steroid Dependent or Refractory Chronic Graft Versus Host Disease

Molecular Targeted Agents / Immunotherapy / Biologics

Pediatric Solid Tumors

COGACCL0922

02/25/2013

SCUSF0901 - ACCL0922: A Phase II Placebo-Controlled Trial of Modafinil to Improve Neurocognitive Deficits in Children Treated for a Primary Brain Tumor

Molecular Targeted Agents / Immunotherapy / Biologics

Leukemia

PRECOGHEM0901

12/04/2012

Phase I Dose Finding/Phase II Placebo-Controlled Trial of Eltrombopag During Consolidation Therapy in Adults with Acute Myeloid Leukemia (AML) in Complete Remission

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBRE1552

02/02/2016

A Randomized Phase II Study of Adjuvant Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination with Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)

Molecular Targeted Agents / Immunotherapy / Biologics

Lung
Non Small Cell

VICCTHO1573

02/01/2016

An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC).

Molecular Targeted Agents / Immunotherapy / Biologics

Leukemia
Pediatric Leukemia

COGAALL1331

02/01/2016

Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

Molecular Targeted Agents / Immunotherapy / Biologics

Multiple Myeloma

VICCHEM15112

01/11/2016

A Phase 1/2 Open-label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound KPT-8602 in Patients with Relapsed/Refractory Multiple Myeloma

Molecular Targeted Agents / Immunotherapy / Biologics

Head/Neck

VICCHN1575

01/08/2016

A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Molecular Targeted Agents / Immunotherapy / Biologics

Neuroblastoma (Pediatrics)

VICCPED1489

01/07/2016

Molecular-Guided Therapy for the Treatment of Patients with Relapsed and Refractory Childhood Cancers

Molecular Targeted Agents / Immunotherapy / Biologics

Hematologic

VICCHEM1565

01/05/2016

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chain (AL) Amyloidosis

Molecular Targeted Agents / Immunotherapy / Biologics

Gastric/Gastroesophageal

VICCGI1515

01/05/2016

A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients with Advanced Solid Tumors

Molecular Targeted Agents / Immunotherapy / Biologics

Neuro-Oncology

ECOGNEUA071102

12/18/2015

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation

Molecular Targeted Agents / Immunotherapy / Biologics

Neuro-Oncology

ECOGNEUA071401

12/18/2015

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Molecular Targeted Agents / Immunotherapy / Biologics

Colon
Esophageal
Head/Neck
Lung
Non Small Cell
Rectal

VICCPHI1598

12/10/2015

A Phase 1 Study Evaluating the Safety, Pharmacology and Preliminary Activity of the Co-Administration of MM-151 and MM-121 in Heregulin Positive Cancer Patients

Molecular Targeted Agents / Immunotherapy / Biologics

Leukemia
Multiple Myeloma

VICCHEM1592

12/09/2015

A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies

Molecular Targeted Agents / Immunotherapy / Biologics

Lung
Non Small Cell

VICCTHO1579

12/09/2015

A Phase 2 Multicenter, Randomized, Placebo Controlled, Double-Blind Study to Assess the Safety and Efficacy of CC -486 (Oral Azacitidine) in Combination with Pembrolizumab (MK-3475) versus Pembrolizumab plus Placebo in Subjects with Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Breast - Female

VICCBRE14101

12/04/2015

Phase I/II Study of BYL719 and Nab-Paclitaxel in Patients with Locally Recurrent or Metastatic HER-2 Negative Breast Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Head/Neck

VICCHN1576

12/04/2015

A Phase 2 Study of TH-4000 in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin

Molecular Targeted Agents / Immunotherapy / Biologics

Sarcoma

COGAEWS1221

12/02/2015

Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma

Molecular Targeted Agents / Immunotherapy / Biologics

Melanoma

ECOGMELS1404

12/01/2015

A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBRE1546

12/01/2015

The Impact of HER2 Heterogeneity on the Treatment of Early- Stage HER2-Positive Breast Cancer: A Phase II Study of T- DM1 in Combination with Pertuzumab in the Preoperative Setting

Molecular Targeted Agents / Immunotherapy / Biologics

Bladder
Breast
Colon
Esophageal
Gastric/Gastroesophageal
Gynecologic
Head/Neck
Kidney (Renal Cell)
Lung
Melanoma
Non Small Cell
Pancreatic
Rectal
Urologic
Uterine

VICCPHI1588

11/27/2015

A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors

Molecular Targeted Agents / Immunotherapy / Biologics

Multiple Myeloma

VICCHEM14131

11/17/2015

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination with Lenalidomide and Dexamethasone in Subjects with Multiple Myeloma

Molecular Targeted Agents / Immunotherapy / Biologics

Lymphoma

VICCHEM14125

11/13/2015

A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

Molecular Targeted Agents / Immunotherapy / Biologics

Lung
Non Small Cell

VICCTHO1556

11/04/2015

A Phase 2 Study of TH-4000 in Patients with EGFR-Mutant, T790M-Negative, Advanced Non-Small Cell Lung Cancer Progressing on an EGFR Tyrosine Kinase Inhibitor

Molecular Targeted Agents / Immunotherapy / Biologics

Colon
Esophageal
Gastric/Gastroesophageal
Liver
Pancreatic
Rectal

VICCGIP1536

10/26/2015

A Phase 1 Study of Alisertib (MLN8237) in combination with mFOLFOX in Gastrointestinal Tumors

Molecular Targeted Agents / Immunotherapy / Biologics

Bones and Joints

VICCSAR1516

10/23/2015

A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects with Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath

Molecular Targeted Agents / Immunotherapy / Biologics

Lung
Non Small Cell

VICCTHO1521

10/16/2015

A Phase III, Open-Label, Randomized, Study of MPDL3280A (Anti-PDL1 Antibody) Compared with Gemcitabine + Cisplatin or CARBOPLATIN for PD-L1-Selected, Chemotherapy Naive Patients with Stage IV Squamous Non-Small Cell Lung Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Bladder
Breast
Hematologic
Leukemia
Lymphoma
Multiple Myeloma
Myelodysplastic Syndrome
Pancreatic
Urologic

VICCHEMP1558

10/09/2015

A Phase 1a/1b, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies

Molecular Targeted Agents / Immunotherapy / Biologics

Head/Neck

VICCHN14139

10/08/2015

A Phase II, Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination with Tremelimumab in Patients with Reucurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN).

Molecular Targeted Agents / Immunotherapy / Biologics

Lung

VICCTHO1519

10/07/2015

A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti−PDL1 Antibody) Compared with Cisplatin or Carboplatin+Pemetrexed for PD-L1−Selected Chemotherapy Naive Patients with Stage Iv Non-Squamous Non−Small Cell Lung Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Pancreatic

VICCGI1421

10/05/2015

A Phase I/II Study of X-82, an Oral Anti-VEGFR Tyrosine Kinase Inhibitor, with Everolimus for Patients with Pancreatic Neuroendocrine Tumors

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBRE1543

09/30/2015

A Phase III, Multicenter, Randomized, Placebo-Controlled Study of MPDL3280A (Anti−PD-L1 Antibody) in Combination with Nab-Paclitaxel Compared with Placebo with Nab-Paclitaxel for Patients with Previously Untreated Metastatic Triple -Negative Breast Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Multiple Myeloma

VICCHEM1437

09/29/2015

A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age

Molecular Targeted Agents / Immunotherapy / Biologics

Lung
Non Small Cell

ECOGTHOE4512

09/15/2015

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Molecular Targeted Agents / Immunotherapy / Biologics

Lung

VICCTHO14128

09/04/2015

A Phase III, Randomised, Double-blind, Placebo-controlled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (PACIFIC)

Molecular Targeted Agents / Immunotherapy / Biologics

Lymphoma
Ovarian

VICCPHI14126

09/03/2015

An OpenLabel Study of the Safety, Tolerability, and Pharmacokinetic / Pharmacodynamic Profile of VX803 as a Single Agent and in Combination With Carboplatin in Subjects With Advanced Solid Tumors or Lymphoma.

Molecular Targeted Agents / Immunotherapy / Biologics

Multiple Myeloma

VICCHEM1509

08/26/2015

An Open-Label, Dose-Escalation and Multi-Center Study to Evaluate the Safety and Pharmacokinetics of SAR650984 in Patients with Relapsed/Refractory Multiple Myeloma

Molecular Targeted Agents / Immunotherapy / Biologics

Ovarian

VICCGYN1518

08/26/2015

A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy versus Physician's Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients Carrying Germline BRCA1/2 Mutations

Molecular Targeted Agents / Immunotherapy / Biologics

Leukemia

VICCHEM1508

08/20/2015

A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy

Molecular Targeted Agents / Immunotherapy / Biologics

VICCGIP1520

07/21/2015

A Phase 1, Open Label, Non Randomized, Dose Escalating Safety, Tolerability, and Pharmacokinetic Study of TAS 102 in Combination with CPT 11 and Bevacizumab In Patients with Advanced Gastrointestinal Tumors

Molecular Targeted Agents / Immunotherapy / Biologics

Other

ECOGEAY131-M

07/16/2015

Molecular Analysis for Therapy Choice

Molecular Targeted Agents / Immunotherapy / Biologics

Pediatric Lymphoma

COGAHOD1331

07/15/2015

A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents

Molecular Targeted Agents / Immunotherapy / Biologics

Lung
Small Cell

VICCTHO1510

07/09/2015

A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Miscellaneous

VICCPHI14136

07/02/2015

An Open-Label, Phase I, Dose-Escalation Trial to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Pharmacokinetics, and Pharmacodynamics of the Anti- FGFR2 Antibody Drug Conjugate BAY 1187982 in Subjects with Advanced Solid Tumors Known to Express FGFR2

Molecular Targeted Agents / Immunotherapy / Biologics

Leukemia
Lymphoma

VICCBMT1406

06/29/2015

A Multi-Center, Phase III, Randomized Trial of Reduced Intensity(RIC) Conditioning and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) versus HLA-Haploidentical Related Bone Marrow (Haplo) for Patients with Hematologic Malignancies

Molecular Targeted Agents / Immunotherapy / Biologics

Pancreatic

VICCGI1507

06/16/2015

NAB-PACLITAXEL (ABRAXANE) plus Gemcitabine in Subjects with Locally Advanced Pancreatic Cancer (LAPC): An International, Open-Label, Multi-Center, Phase 2 Study (LAPACT)

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBRE1374

06/15/2015

Phase Ib/II Trial of Taselisib (GDC-0032), a PI3K Inhibitor, in Combination with Enzalutamide in Patients with Androgen Receptor Positive Triple Negative Metastatic Breast Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBREP14115

05/21/2015

An Open-Label, Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

VICCHEMP14114

05/20/2015

A Phase 1, Open-label, Multicenter, Randomized, 2-Period Crossover Study to Evaluate the Bioequivalence of CC-486 (Oral Azacitidine) Tablets in Adult Cancer Subjects

Molecular Targeted Agents / Immunotherapy / Biologics

Leukemia

VICCHEM1505

05/06/2015

An Open-Label Phase I Dose-Escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 1143572 given in a Once-Daily or an Intermittent Dosing Schedule in Subjects with Advanced Acute Leukemia

Molecular Targeted Agents / Immunotherapy / Biologics

Melanoma

VICCMEL1486

05/01/2015

A Multicenter Phase II Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) in Patients with Advanced Uveal Melanoma

Molecular Targeted Agents / Immunotherapy / Biologics

Head/Neck

VICCHN14121

04/23/2015

A Phase II Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Molecular Targeted Agents / Immunotherapy / Biologics

Soft Tissue

COGARST1321

04/21/2015

Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC#737754, IND# 118613)

Molecular Targeted Agents / Immunotherapy / Biologics

Lymphoma

VICCHEM1490

04/07/2015

Phase 1/2 Open-label, Multiple-dose, Dose-escalation Study to Evaluate the Safety and Tolerability of IMO-8400 in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma and MyD88 L265P Mutation

Molecular Targeted Agents / Immunotherapy / Biologics

Lung
Non Small Cell

ECOGTHOS1400

04/02/2015

Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBRE1480

03/31/2015

A Randomized, Multicenter, Open Label Study of MM-302 plus Trastuzumab vs. Chemotherapy of Physician's Choice plus Trastuzumab in Anthracycline Naive Patients with Locally Advanced/Metastatic HER2-Positive Breast Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBRE1246

03/13/2015

Enhancing Efficacy of Chemotherapy in Triple-Negative/Basal-Like Breast Cancers by Targeting Macrophages: A Phase Ib/II Study of PLX3397 and Eribulin in Patients with Metastatic Breast Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Lung
Non Small Cell

VICCTHO1443

03/11/2015

A Phase III, Randomized, Open-Label, Cross-Over, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane?) as Maintenance Treatment after Induction with Nab-Paclitaxel Plus Carboplatin in Subjects with Squamous Cell Non-Small Cell Lung Cancer (NSCLC)

Molecular Targeted Agents / Immunotherapy / Biologics

Neuroendocrine
Pancreatic

ECOGGIE2211

03/04/2015

A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors

Molecular Targeted Agents / Immunotherapy / Biologics

Sarcoma

VICCSAR1483

02/26/2015

SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients with Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas

Molecular Targeted Agents / Immunotherapy / Biologics

Melanoma

VICCMEL1471

02/04/2015

A Phase 1b/2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 232 Combined with Trametinib and Dabrafenib or Trametinib in Adult Subjects with Metastatic Cutaneous Melanoma

Molecular Targeted Agents / Immunotherapy / Biologics

VICCGI1497

01/27/2015

A Multi-Institutional, Single-Arm, Two-Stage Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients with Advanced or Metastatic Cholangiocarcinoma

Molecular Targeted Agents / Immunotherapy / Biologics

Melanoma

VICCPHI13113

01/22/2015

A Multicenter Phase 1 Ascending Dose Study of DCC-2701 to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Solid Tumors.

Molecular Targeted Agents / Immunotherapy / Biologics

Melanoma

VICCMEL1457

01/19/2015

A Phase II Open-Label, Two-Arm Study of the MEK Inhibitor, Trametinib, to Investigate the Safety and Anti-Cancer Activity in Subjects with Melanoma with BRAF non-V600 Mutations

Molecular Targeted Agents / Immunotherapy / Biologics

Prostate

VICCURO1473

01/09/2015

A Randomized Phase II Study of Androgen Deprivation Therapy with or without PD 0332991 in RB-Positive Metastatic Hormone-Sensitive Prostate Cancer.

Molecular Targeted Agents / Immunotherapy / Biologics

Pancreatic

VICCGI1417

12/17/2014

A Phase 1b Dose Escalation Study of Ipafricept (OMP-54F28) in Combination with Nab-Paclitaxel and Gemcitabine in Patients with Previously Untreated Stage IV Pancreatic Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBRE1453

11/18/2014

A Phase 2, Open-Label, Multicenter, Safety and Efficacy Study of Oral Lucitanib in Patients with FGF Aberrant Metastatic Breast Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Lung
Non Small Cell

VICCTHO1478

11/14/2014

A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination with Ascending Doses of Novel Therapeutics in Patients with EGFRm+ Advanced NSCLC who have progressed following therapy with an EGFR TKI (TATTON)

Molecular Targeted Agents / Immunotherapy / Biologics

Myelodysplastic Syndrome

VICCHEM1487

11/10/2014

A Phase 1-2 Pharmacokinetic Guided Dose-Escalation and Dose-Confirmation Study of ASTX727, a Combination of the Oral Cytidine Deaminase Inhibitor (CDAi) E7727 with Oral Decitabine in Subjects with Myelodysplastic Syndromes (MDS)

Molecular Targeted Agents / Immunotherapy / Biologics

Pediatric Lymphoma

COGANHL12P1

10/20/2014

A Randomized Phase II Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, commercially labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL) IND # 117117

Molecular Targeted Agents / Immunotherapy / Biologics

Lung
Non Small Cell

VICCTHO1467

10/02/2014

A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Systemic Regimen

Molecular Targeted Agents / Immunotherapy / Biologics

Lymphoma

VICCHEM1402

09/15/2014

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Molecular Targeted Agents / Immunotherapy / Biologics

Multiple Myeloma

VICCHEM1448

09/09/2014

A Multicenter Phase 1/2b Study of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination with Carfilzomib (Kyprolis TM) in Subjects with Relapsed or Relapsed and Refractory Multiple Myeloma

Molecular Targeted Agents / Immunotherapy / Biologics

Lung
Non Small Cell

VICCTHN13111

08/27/2014

A Phase III, Randomized, Double-Blind, Placebo-Controlled Multicenter Trial of Bavituximab Plus Docetaxel versus Docetaxel Alone in Patients with Previously Treated Stage IIIb/IV Non-Squamous Non-Small-Cell Lung Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

VICCPHI1436

08/18/2014

A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-119 in Combination with Paclitaxel in Patients with Advanced Solid Tumors

Molecular Targeted Agents / Immunotherapy / Biologics

Prostate

VICCURO1450

08/13/2014

PROSPER: A Multinational, Phase 3, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Enzalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBRE1430

08/12/2014

A Phase 2, Multicenter, Open-label Study to Assess the Efficacy and Safety of Enzalutamide with Trastuzumab in Subjects with HER2+ AR+ Metastatic or Locally Advanced Breast Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Leukemia

VICCHEM1423

08/08/2014

A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation

Molecular Targeted Agents / Immunotherapy / Biologics

Pancreatic

VICCGI1405

08/07/2014

A Phase 3, Multicenter, Open-Label, Randomized Study of nab?-Paclitaxel Plus Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma

Molecular Targeted Agents / Immunotherapy / Biologics

Colon

VICCGI13104

08/06/2014

A Phase 2 Clinical Trial of Nivolumab and Nivolumab Plus Ipilimumab in Recurrent and Metastatic Microsatellite High (MSI-H) Colon Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Esophageal
Gastric/Gastroesophageal

VICCGI13114

08/04/2014

A Four Part, Phase 1, Multi-center, Open-label Study of DKN-01 in Combination with Weekly Paclitaxel; Part A: A Dose-Escalation Study in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Part B: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Part C: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal or Gastro-esophageal Junction Adenocarcinoma; Part D: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Squamous Cell Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBRE1393

06/23/2014

A Phase II Randomized, Double-Blind Placebo Controlled, Study of Letrozole with or without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women with Hormone Receptor-Positive HER2-Negative Breast Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Bladder
Colon
Esophageal
Gastric/Gastroesophageal
Neuro-Oncology
Ovarian
Urologic
Uterine

VICCMD1403

06/02/2014

An Open Label, Phase II Study of Neratinib in Patients with Solid Tumors with Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification

Molecular Targeted Agents / Immunotherapy / Biologics

VICCPHI1387

05/28/2014

A Phase Ib, Open-Label, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of MEHD7945A and Cobimetinib in Patients with Locally Advanced or Metastatic Cancers with Mutant KRAS

Molecular Targeted Agents / Immunotherapy / Biologics

VICCPHI1375

05/16/2014

Phase I Dose Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients with Advanced Malignancies BVD-523-01

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBRE1391

04/24/2014

A Phase III, Randomized, Open Label, Multicenter, Controlled Trial of Niraparib versus Physician's Choice in Previously-Treated, HER2-Negative, Germline BRCA Mutation-Positive Breast Cancer Patients

Molecular Targeted Agents / Immunotherapy / Biologics

Lymphoma

VICCHEM13105

04/09/2014

A Single-Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects with Relapsed or Refractory Follicular Lymphoma (FL)

Molecular Targeted Agents / Immunotherapy / Biologics

Hematologic

VICCHEM1274

03/31/2014

A Phase 3 Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physicians Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

Molecular Targeted Agents / Immunotherapy / Biologics

Breast - Female

VICCBREP1363

03/21/2014

A Phase Ib/II, Multicenter, Study of the Combination of LEE011 and BYL719 with Letrozole in Adult Patients with Advanced ER+ Breast Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Pancreatic

VICCGI1370

12/30/2013

A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination with Nab-Paclitaxel and Gemcitabine in Patients with Previously Untreated Stage IV Pancreatic Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Breast - Female
Breast - Male

ECOGBRES1207

10/31/2013

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e3 Breast Cancer Study- evaluating everolimus with endocrine therapy.

Molecular Targeted Agents / Immunotherapy / Biologics

VICCPHI1255

09/28/2013

Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, a C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBRE1320

08/16/2013

A Phase Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0032 in Combination with Either Docetaxel or Paclitaxel in Patients with HER2-Negative Locally Recurrent or Metastatic Breast Cancer or Non-Small Cell Lung Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Neuroendocrine
Pancreatic

VICCGI1250

04/09/2013

A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumors (PNET)

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCBREP12116

03/25/2013

An Open-Label, Phase IA/IB/IIA Study of GDC-810 Alone or in Combination With Palbociclib and an LHRH Agonist in Women with Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Prostate

VICCURO1260

03/19/2013

A Phase I Study of Cabazitaxel, Mitoxantrone, and Prednisone (CAMP) for Patients with Metastatic Castration-Resistant Prostate Cancer and no Prior Chemotherapy

Molecular Targeted Agents / Immunotherapy / Biologics

Esophageal

VICCGI1211

03/08/2013

Phase IB/II Study of Induction Chemotherapy with XELOX, followed by Radiation Therapy, Carboplatin and RAD001 in Patients with Esophageal Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

VICCPHI1248

10/12/2012

An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC0032 in Patients with Locally Advanced or Metastatic Solid Tumors and in Combination with Endocrine Therapy in Patients with Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Lymphoma

VICCHEM1146

08/14/2012

Ofatumumab in Combination with High Dose Cytarabine Chemoimmunotherapy for Patients with Newly Diagnosed Mantle Cell Lyjmphoma

Molecular Targeted Agents / Immunotherapy / Biologics

Neuroblastoma (Pediatrics)
Pediatric Solid Tumors

VICCPED1249

08/06/2012

An Open Label, Expanded Access Protocol using 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy in Patients with Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

Molecular Targeted Agents / Immunotherapy / Biologics

Lung
Non Small Cell

VICCTHN1244

07/25/2012

Phase 1, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of X-396 in Patients with Advanced Solid Tumors

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

CTSUNSABPBREB-47-M

04/26/2012

A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer 

Molecular Targeted Agents / Immunotherapy / Biologics

Breast

CTSUBRENB-43-M

04/26/2012

A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy

Molecular Targeted Agents / Immunotherapy / Biologics

VICCPHI1138

03/08/2012

A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously as a Single Agent to Patients with Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies

Molecular Targeted Agents / Immunotherapy / Biologics

Non Small Cell

ECOGTHO5508-M

02/09/2011

Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC

Molecular Targeted Agents / Immunotherapy / Biologics

Liver

CTSUGIC80802-M

12/07/2010

Phase III randomized study of sorafenib (IND 69896, NSC 724772) plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC)

Molecular Targeted Agents / Immunotherapy / Biologics

Lung

CTSUTHOC30607-M

02/17/2010

ARandomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB/IV Non-Small Cell Lung Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Head/Neck

ECOGHNE1305-M

02/11/2009

A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer

Molecular Targeted Agents / Immunotherapy / Biologics

Non Small Cell

ECOGTHOE1505-M

07/27/2007

A Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (> or = 4 cm)- IIIA Non-Small Cell Lung Cancer (NSCLC)